KAPA (Kairos Pharma) 10-Year Share Buyback Ratio: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAPA Kairos Pharma Ltd KAPA
15 GF Score
Price $1.76
View Full Analysis

What is Kairos Pharma 10-Year Share Buyback Ratio?

Kairos Pharma KAPA +4.64% 15 10-Year Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus rates KAPA with a GF Score™ of 15/100. Among 658 Biotechnology companies, Kairos Pharma ranks worse than 151975.53% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Kairos Pharma's current 10-Year Share Buyback Ratio was 0.00%.

KAPA's 10-Year Share Buyback Ratio is not ranked *
in the Biotechnology industry.
Industry Median: -12.15
* Ranked among companies with meaningful 10-Year Share Buyback Ratio only.

Kairos Pharma (AMEX:KAPA) 10-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Kairos Pharma 10-Year Share Buyback Ratio Related Terms

KAPA vs NIKI, LIMN, JUNS: 10-Year Share Buyback Ratio Comparison

For the Biotechnology subindustry, Kairos Pharma's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kairos Pharma 10-Year Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kairos Pharma's 10-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Kairos Pharma's 10-Year Share Buyback Ratio falls into.


KAPA
15GF Score
Kairos Pharma Ltd KAPA
10-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kairos Pharma 10-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 10-Year Share Buyback Ratio of 0.00 mean?
Kairos Pharma (KAPA) has a 10-Year Share Buyback Ratio of 0.00 as of Jun. 2026. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Kairos Pharma and its competitors. According to the industry distribution chart, Kairos Pharma ranks #999999 out of 658 companies in the Biotechnology industry.
Is Kairos Pharma's 10-Year Share Buyback Ratio too high?
Kairos Pharma's current 10-Year Share Buyback Ratio is 0.00. Based on the distribution chart, Kairos Pharma ranks #999999 out of 658 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kairos Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Kairos Pharma's 10-Year Share Buyback Ratio compare to NIKI and LIMN?
According to the Biotechnology industry distribution chart, Kairos Pharma ranks #999999 out of 658 companies for 10-Year Share Buyback Ratio. This places Kairos Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Share Buyback Ratio for a Biotechnology company?
A good 10-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 10-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Share Buyback Ratio mean?
A high 10-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Kairos Pharma and its competitors. Kairos Pharma's current 10-Year Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kairos Pharma stock overvalued right now?
Kairos Pharma (KAPA) has a current 10-Year Share Buyback Ratio of 0.00. The current 10-Year Share Buyback Ratio is 0.00. Kairos Pharma's overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Share Buyback Ratio calculated?
10-Year Share Buyback Ratio is calculated from a company's financial statements. For Kairos Pharma (KAPA), the current 10-Year Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kairos Pharma Business Description

Address 2355 Westwood Boulevard, No. 139, Los Angeles, CA, USA, 90064
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
15GF Score

Get the complete analysis for KAPA

10-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.76
Price